1,221
Participants
Start Date
March 31, 2007
Primary Completion Date
June 30, 2009
Study Completion Date
June 30, 2009
RISPERDAL CONSTA
RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
Paliperidone palmitate
PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
Birmingham
Little Rock
Cerritos
Garden Grove
Los Angeles
Washington D.C.
Atlanta
Chicago
Flowood
Hollis
Willoughby
Oklahoma City
DeSoto
Houston
Odessa
Linz
Salzburg
Vienna
Plovdiv
Varna
Brno
Dobřany
Kroměříž
Kutná Hora
Olomouc
Prague
Pärnu
Tallinn
Tartu
Bourges Cedex N/A
Dole
Romans-sur-Isère
Achim
Berlin
Bielefeld
Bochum
Jena
Leipzig
Mannheim
München
Stralsund
Baja
Budapest
Gyõr
Kalocsa
Nagykálló
Aurangabad
Bangalore
Chandigarh
Mangalore
Pune
Varanasi
Alytus
Kaunas
Klaipėda
Vilnius
Bełchatów
Bytom Na
Chełmno
Gdynia Na
Katowice Woj Slaskie
Krakow Na
Lubliniec
Piekary Slaskie Na
Skorzewo Na
Warszawa Na
Moscow
Moscow Russia
Nizny Novgorod
Saint Petersburg
Saratov
Yaroslavl
Barcelona
Madrid
San Juan
Dnipro
Donetsk
Kharkiv
Kiev
Kyiv
Odesa
Simferopol
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY